Figure 3.

Transitional B cells increased in  NEDA patients following DMF treatment. Representation of percentages (%) of transitional B lymphocytes (CD27⁻ IgD⁺ CD24hi CD38hi) from the total of B cells (CD3⁻ CD19⁺ cells), before the treatment (Baseline) and after 1, 3, 6, and 12 months of follow‐up in total RRMS patients (n = 22) (A), and after been classified in NEDA (n = 15) (B) and ODA (n = 6) (C) groups. Data are expressed as mean SD. Each dot represents the value of an individual. *P < 0.05, **P < 0.01 and ***P < 0.001